Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025.

Saved in:
Bibliographic Details
Title: Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025.
Authors: Rose AM; Epiconcept, Paris, France.; These authors contributed equally as first authors.; These authors contributed equally to the writing of the paper., Lucaccioni H; Epiconcept, Paris, France.; These authors contributed equally as first authors., Marsh K; Public Health Scotland, NHS Scotland, Glasgow, United Kingdom., Kirsebom F; UK Health Security Agency, London, England., Whitaker H; UK Health Security Agency, London, England., Emborg HD; Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark., Bolt Botnen A; Department of Virology and Microbiological Preparedness, Statens Serum Institut, Copenhagen, Denmark., O'Doherty MG; Public Health Agency, Belfast, United Kingdom., Pozo F; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain., Hameed SS; Public Health Scotland, NHS Scotland, Glasgow, United Kingdom., Andrews N; UK Health Security Agency, London, England., Hamilton M; Public Health Scotland, NHS Scotland, Glasgow, United Kingdom., Trebbien R; Department of Virology and Microbiological Preparedness, Statens Serum Institut, Copenhagen, Denmark., Lauenborg Møller K; Data Integration and Analyses, Statens Serum Institut, Copenhagen, Denmark., Marques DF; Epiconcept, Paris, France., Murphy S; Public Health Agency, Belfast, United Kingdom., McQueenie R; Public Health Scotland, NHS Scotland, Glasgow, United Kingdom., Lopez-Bernal J; UK Health Security Agency, London, England., Cottrell S; Public Health Wales, Cardiff, Wales., Bucholc M; Public Health Agency, Belfast, United Kingdom., Kissling E; Epiconcept, Paris, France.; These authors contributed equally to the writing of the paper.
Corporate Authors: European IVE group; European Influenza Vaccine Effectiveness (IVE) group members are listed under Collaborators., Members of the European IVE group
Source: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2025 Feb; Vol. 30 (7).
Publication Type: Journal Article
Journal Info: Publisher: European Centre for Disease Prevention and Control (ECDC) Country of Publication: Sweden NLM ID: 100887452 Publication Model: Print Cited Medium: Internet ISSN: 1560-7917 (Electronic) Linking ISSN: 1025496X NLM ISO Abbreviation: Euro Surveill Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39980423
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Rose+AM%22">Rose AM</searchLink>; Epiconcept, Paris, France.; These authors contributed equally as first authors.; These authors contributed equally to the writing of the paper.<br /><searchLink fieldCode="AU" term="%22Lucaccioni+H%22">Lucaccioni H</searchLink>; Epiconcept, Paris, France.; These authors contributed equally as first authors.<br /><searchLink fieldCode="AU" term="%22Marsh+K%22">Marsh K</searchLink>; Public Health Scotland, NHS Scotland, Glasgow, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Kirsebom+F%22">Kirsebom F</searchLink>; UK Health Security Agency, London, England.<br /><searchLink fieldCode="AU" term="%22Whitaker+H%22">Whitaker H</searchLink>; UK Health Security Agency, London, England.<br /><searchLink fieldCode="AU" term="%22Emborg+HD%22">Emborg HD</searchLink>; Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Bolt+Botnen+A%22">Bolt Botnen A</searchLink>; Department of Virology and Microbiological Preparedness, Statens Serum Institut, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22O'Doherty+MG%22">O'Doherty MG</searchLink>; Public Health Agency, Belfast, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Pozo+F%22">Pozo F</searchLink>; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.; National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Hameed+SS%22">Hameed SS</searchLink>; Public Health Scotland, NHS Scotland, Glasgow, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Andrews+N%22">Andrews N</searchLink>; UK Health Security Agency, London, England.<br /><searchLink fieldCode="AU" term="%22Hamilton+M%22">Hamilton M</searchLink>; Public Health Scotland, NHS Scotland, Glasgow, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Trebbien+R%22">Trebbien R</searchLink>; Department of Virology and Microbiological Preparedness, Statens Serum Institut, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Lauenborg+Møller+K%22">Lauenborg Møller K</searchLink>; Data Integration and Analyses, Statens Serum Institut, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Marques+DF%22">Marques DF</searchLink>; Epiconcept, Paris, France.<br /><searchLink fieldCode="AU" term="%22Murphy+S%22">Murphy S</searchLink>; Public Health Agency, Belfast, United Kingdom.<br /><searchLink fieldCode="AU" term="%22McQueenie+R%22">McQueenie R</searchLink>; Public Health Scotland, NHS Scotland, Glasgow, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Lopez-Bernal+J%22">Lopez-Bernal J</searchLink>; UK Health Security Agency, London, England.<br /><searchLink fieldCode="AU" term="%22Cottrell+S%22">Cottrell S</searchLink>; Public Health Wales, Cardiff, Wales.<br /><searchLink fieldCode="AU" term="%22Bucholc+M%22">Bucholc M</searchLink>; Public Health Agency, Belfast, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Kissling+E%22">Kissling E</searchLink>; Epiconcept, Paris, France.; These authors contributed equally to the writing of the paper.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22European+IVE+group%22">European IVE group</searchLink>; European Influenza Vaccine Effectiveness (IVE) group members are listed under Collaborators.<br /><searchLink fieldCode="CA" term="%22Members+of+the+European+IVE+group%22">Members of the European IVE group</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100887452%22">Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</searchLink> [Euro Surveill] 2025 Feb; Vol. 30 (7).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22European+Centre+for+Disease+Prevention+and+Control+%28ECDC%29%22">European Centre for Disease Prevention and Control (ECDC) </searchLink><i>Country of Publication: </i>Sweden <i>NLM ID: </i>100887452 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1560-7917 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%221025496X%22">1025496X </searchLink><i>NLM ISO Abbreviation: </i>Euro Surveill <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39980423
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.2807/1560-7917.ES.2025.30.7.2500102
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Rose AM
      – PersonEntity:
          Name:
            NameFull: Lucaccioni H
      – PersonEntity:
          Name:
            NameFull: Marsh K
      – PersonEntity:
          Name:
            NameFull: Kirsebom F
      – PersonEntity:
          Name:
            NameFull: Whitaker H
      – PersonEntity:
          Name:
            NameFull: Emborg HD
      – PersonEntity:
          Name:
            NameFull: Bolt Botnen A
      – PersonEntity:
          Name:
            NameFull: O'Doherty MG
      – PersonEntity:
          Name:
            NameFull: Pozo F
      – PersonEntity:
          Name:
            NameFull: Hameed SS
      – PersonEntity:
          Name:
            NameFull: Andrews N
      – PersonEntity:
          Name:
            NameFull: Hamilton M
      – PersonEntity:
          Name:
            NameFull: Trebbien R
      – PersonEntity:
          Name:
            NameFull: Lauenborg Møller K
      – PersonEntity:
          Name:
            NameFull: Marques DF
      – PersonEntity:
          Name:
            NameFull: Murphy S
      – PersonEntity:
          Name:
            NameFull: McQueenie R
      – PersonEntity:
          Name:
            NameFull: Lopez-Bernal J
      – PersonEntity:
          Name:
            NameFull: Cottrell S
      – PersonEntity:
          Name:
            NameFull: Bucholc M
      – PersonEntity:
          Name:
            NameFull: Kissling E
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2025 Feb
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1560-7917
          Numbering:
            – Type: volume
              Value: 30
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
              Type: main
ResultId 1